Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virxsys Corp.

www.virxsys.com

Latest From Virxsys Corp.

Gene therapy: a technology whose time has come?

It is now almost 20 years since the first patient was enrolled into an officially sanctioned gene therapy study, and in that time the field has been through a series of successes and setbacks. Today, it remains the case that only two gene therapy products have ever been approved anywhere in the world, but interest in gene therapy remains keen.

Gastrointestinal Cardiovascular

Takara Bio allies with US university for novel HIV gene therapy

Takara Bio has signed a collaborative research agreement with the University of Pennsylvania in the US for the co-development of an innovative gene-based therapy for HIV.

Infectious Diseases Cancer

Gene Therapy: The Next Big Thing?

Investors' and Big Pharmas' hitherto frosty view of gene-based medicines may be starting to thaw, at least in places, warmed by clinical progress and a smattering of deals. Is there any real potential in this market? Until the first FDA approval, no-one's expecting any real heat. But there are companies which are enjoying limited success in the early stages, whose experience most likely reflects where at least the near-term potential of gene-based medicines lie.
BioPharmaceutical Business Strategies

Lentigen Corp.

Lentigen has big plans for its HIV-1 based lentiviral vector technology. Short term, it plans to leverage its platform to become the leading provider of lentiviral vector research products and services to academic, government and biopharma scientists. These revenues will help cover the company's burn rate and fund future therapeutic product development programs.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Virxsys Corp.
  • Senior Management
  • Gerard Fleury, EVP, CFO
    Laurent Humeau, PhD, VP, R&D
  • Contact Info
  • Virxsys Corp.
    Phone: (301) 987-0480
    200 Perry Pkwy., Ste. 1A
    Gaithersburg, MD 20877
    USA
UsernamePublicRestriction

Register